Critical Contrast: SQZ Biotechnologies (NYSE:SQZ) and Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Galectin Therapeutics and SQZ Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Risk & Volatility

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Institutional and Insider Ownership

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Galectin Therapeutics and SQZ Biotechnologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.43)	-10.26
SQZ Biotechnologies	$18.16 million	0.04	-$79.46 million	($2.61)	-0.01

Galectin Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Galectin Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Galectin Therapeutics and SQZ Biotechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1	1	1	0	2.00
SQZ Biotechnologies	0	0	0	0	0.00

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 149.43%. Given Galectin Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than SQZ Biotechnologies.

Summary

Galectin Therapeutics beats SQZ Biotechnologies on 8 of the 13 factors compared between the two stocks.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.